Metyrapone Esteve

Metyrapone, the active ingredient in Metyrapone Esteve, is a 11β-hydroxylase inhibitor presented as an oral formulation for oral use. It is employed in the diagnostic evaluation of adrenal insufficiency and may be used therapeutically to support patients with this condition.

GNH USA supplies Metyrapone Esteve as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metyrapone acts on adrenal steroidogenesis and is used in the assessment and management of adrenal disorders.

- Diagnostic testing for adrenal insufficiency: facilitates evaluation of the hypothalamic‑pituitary‑adrenal axis by transiently blocking cortisol synthesis. - Treatment of adrenal insufficiency: provides supplemental cortisol support when endogenous production is inadequate.

Metyrapone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness, especially on standing. - Headache: occasional tension‑type headache. - Fatigue: feeling unusually tired or weak. - Abdominal pain: cramp‑like discomfort in the stomach area.

Serious or Rare Side Effects: - Adrenal crisis: severe cortisol deficiency requiring urgent medical care. - Hypotension: marked drop in blood pressure that may cause fainting. - Allergic reaction: rash, itching, or swelling of the face and throat. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury. - Hyponatremia or hypoglycemia: low sodium or blood sugar levels that can be life‑threatening.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Monitor cortisol levels: assess hormonal response regularly. - Assess adrenal function: confirm diagnosis before use. - Adjust for hepatic impairment: consider dose reduction in liver disease. - Use cautiously in the elderly: increased sensitivity to hypotension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metyrapone can alter the metabolism of several concomitant medicines, requiring attention to interaction risk.

Major Interactions (Avoid): - Ketoconazole: additive inhibition of steroid synthesis may precipitate adrenal crisis. - Rifampicin: strong enzyme induction reduces metyrapone effectiveness. - Carbamazepine: enhances hepatic metabolism, lowering drug levels.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may decrease hormonal efficacy. - SSRIs (e.g., fluoxetine): potential for altered cortisol dynamics. - NSAIDs: may increase risk of gastrointestinal irritation.